Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma

NCT01622439 is registered in ClinicalTrials.gov with Lund University Hospital as lead sponsor.

NCT NCT01622439
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01622439 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma
Lead sponsor
Lund University Hospital
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2012
Completion date
March 31, 2018
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma